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Abstract
Background: Aberrant expression of Retinoic acid receptor γ (RARγ) is implicated in cancer development. Our
previous study identified that RARγ functions as a tumor promoter to drive hepatocellular carcinoma (HCC) growth.
However, its contribution to HCC invasion and metastasis remains unclear.
Methods: RARγ expression in clinical HCC samples was detected by western blot and immunohistochemistry. The
relationship between RARγ expression levels and the clinical characteristics were evaluated. HCC cell line MHCC-97H
were stably knocked down RARγ using a lentivirus vector-based shRNA technique. The cells were analyzed by
migration and invasion assays, and injected into nude mice to assess tumor metastasis. E-cadherin expression
regulated by RARγ was examined by qPCR, western blot and immunofluorescence staining.
Results: The expression of RARγ is significantly upregulated in human HCC tissues. Moreover, its expression
positively correlates with tumor size, distant metastasis and TNM stage, and negatively correlates with length of
survival of HCC patients. Knockdown of RARγ markedly inhibits HCC cell invasion and metastasis both in vitro and
in vivo. Mechanistic investigations reveal that RARγ functions through regulation of NF-κB-mediated E-cadherin
downregulation to promote HCC invasion and metastasis. Notably, RARγ expression status negatively correlates
with E-cadherin expression in HCC cell lines and clinical HCC samples.
Conclusions: These findings demonstrate that RARγ could promote HCC invasion and metastasis by regulating
E-cadherin reduction, and implicate new strategies to aggressively treat HCC through targeting RARγ/E-cadherin
signaling axis.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common cancer types worldwide, particularly in China
[1, 2]. HCCs that undergo early vascular invasion are
highly resistant to existing therapies, such as chemo-
therapy [3]. Although current advances have been made
in the diagnosis of HCC, the overall survival rate of the
HCC patients is disappointingly low due to recurrence
and metastasis [4, 5]. Extensive studies have identified
that many risk factors such as hepatitis B (HBV) and
hepatitis C (HCV), and dysregulation of signaling path-
way and molecules, are implicated in HCC development
[6, 7]. However, little is known about how HCC
undergoes metastasis. Therefore, identifying potential
molecular mechanisms contributing to the metastasis of
HCC is one of the most critical issues.
Metastasis, a complex biological process that involves
tumor cells detaching from the primary tumor, migrating
and locating in distant organs, is the principal cause
leading to death in all types of cancer including HCC
[8, 9]. Significant advances have been made in under-
standing the molecular mechanisms underlying metas-
tasis, and several signalings and molecules have been
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identified [10]. Accumulating evidence indicates that
epithelial-mesenchymal transition (EMT) is a crucial
step for cancer cell invasion and metastasis initiation
[11]. Downregulation of E-cadherin, a single-span trans-
membrane glycoprotein located primarily within adherent
junction, is a fundamental feature of EMT [8, 12–14]. Loss
of E-cadherin correlates with poorer survival for patients
with numerous cancers such as gastric cancer and HCC
[15, 16]. Loss or reduction of E-cadherin expression in
human tumors can be caused by somatic mutations,
chromosomal deletions, DNA methylation and several
intracellular EMT-inducers like Twist, Snail, Slug, Zeb1,
Zeb2 and others [17–26]. For example, somatic point mu-
tations of the E-cadherin gene [17] and/or promoter
methylation lead to E-cadherin loss [20, 27], and the loss
of E-cadherin expression is considered to be a distinguish-
ing feature in both lobular breast cancer and diffuse
gastric cancer [27, 28]. Transcriptional repressors, such as
Snail, Slug and Twist, directly bind to the E-cadherin pro-
moter to transcriptionally repress E-cadherin expression
in breast cancer [22, 29]. We recently also reported that
Nur77, an orphan member of the nuclear receptor
superfamily, induces E-cadherin reduction in a Matrix
metalloproteinase 9 (MMP-9)-dependent manner, and
subsequently contributes to the invasion and metastasis of
colorectal cancer [8]. Despite these efforts to understand
the molecular mechanism of E-cadherin ablation or re-
duction in cancer, however, regulation of E-cadherin
expression in cancer is still poorly understood.
Retinoic acid receptor γ (RARγ) is a member of the
nuclear receptor subfamily. Recent studies implicate
RARγ in cancer development and progression. A lot of
efforts have been made to explore the regulatory mech-
anism of RARγ in cancer, but there are contradictory
views regarding its role in cancer. On one hand, RARγ
may function as an oncogene to drive cancer cell growth
and metastasis. For example, RARγ upregulation in chol-
angiocarcinoma contributes to cancer cell growth and
metastasis [30]. We previously also reported that RARγ
is overexpressed in HCC and overexpression of RARγ
endows HCC cells with malignancy types [31]. In con-
trast, RARγ has also been reported as a tumor suppres-
sion factor that inhibits cancer cells proliferation and
invasion. For example, RARγ, by regulating the expres-
sion of carbohydrate sulfotransferase 10 (CHST10), can
suppress melanoma invasion [32]. Loss of RARγ, but not
RARα, promotes v-Ha-Ras-induced squamous cell car-
cinoma [33]. Recently, we reported that RARγ is down-
regulated in clinical colorectal cancer tissues, and RARγ
acts as a tumor suppressor to regulate colorectal tumori-
genesis and metastasis by restricting the Hippo-Yap
pathway-mediated oncogenic signaling [34]. Taken to-
gether, these results strongly indicated that RARγ plays a
pivotal role in cancer development. However, it is
unknown whether and how RARγ is involved in HCC
invasion and metastasis.
In the present study, we investigated the role of RARγ
in the invasion and metastasis of HCC. Our in vitro and
in vivo studies demonstrate that RARγ, acting through
NF-κB-mediated E-cadherin reduction, drives HCC cell
invasion and metastasis. In clinical HCC samples, we ob-
served a statistical correlation between elevated RARγ ex-
pression and distant metastasis and poor survival. These
findings implicate that nuclear receptor RARγ may be
used as a new potential target for aggressive HCC therapy.
Methods
Antibody and regents
Anti-RARγ, anti-E-cadherin and anti-Myc tag antibodies
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). all-trans-RA (ATRA) and anti-β-actin
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Lipofectamine 2000 and TRIZOL reagent were
purchased from Invitrogen (Carlsbad, CA, USA) and
WesternBright ECL reagents were purchased from
Advansta (Menlo Park, CA, USA).
Cell culture
The QGY-7703, MHCC-97H, SMMC-7721, BEL-7402,
SK-HEP-1 and Huh-7 human hepatocellular carcinoma
cell lines were purchased from the Cell Bank of the
Chinese Academy of Sciences (Shanghai, China). These
cells were cultured in DMEM medium containing 10 %
fetal bovine serum at 37 °C in a humidified 5 % CO2
atmosphere.
Tissue samples and evaluation
Fifty-six human HCC tissues were obtained from the
First Affiliated Hospital of Soochow University (Suzhou,
Jiangsu, China) from 2012 to 2013. Expression levels of
RARγ and E-cadherin were scored using immunohisto-
chemistry in all tissues. The clinical characteristics of all
patients included in this study are listed in Table 1. The
correlation of RARγ expression and patients' survival
outcomes were illustrated using a HCC tissue microarray
(Outdo Biotech Co., Ltd, Shanghai, China) containing 90
HCC samples with survival time. These samples were col-
lected between 2002 and 2009. The study was approved
by Soochow University for Biomedical Research Ethics
Committee, and all of the patients provided informed
consent. The staining score was evaluated as recently
described [35, 36].
Generation of stable cell lines
MHCC-97H cell lines stably expressing RARγ-specific
shRNA (shRNA/RARγ) or scrambled shRNA control
(shRNA/Control) were constructed using a lentiviral
shRNA technique (GeneChem, Shanghai, China). The
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detailed protocol has been described recently [8]. The
human RARγ shRNA target sequences were as follows:
shRNA/RARγ 1#, 5'-CTCCCTTAATCCGAGAGAT-3'; and
shRNA/RARγ 2#, 5'-CTCAGTTAGAAGAGCTCAT-3'.
Western blot and immunofluorescence stainng
Western blot was performed as described recently [8]. Pro-
tein expression was detected using primary and secondary
antibodies, and visualized using enhanced chemilumines-
cence reagents and autoradiography. Representative blots
are shown from three independent experiments. Cells for
immunofluorescence staining were grown and stained as
previously described [37]. The images were taken with a
Nikon ECLIPSE Ni scope with color camera and were
processed by NIS-Elements D 4.10.00 software.
RNA extraction and qPCR analysis
Total RNAs were extracted and reverse transcribed as re-
cently described [8, 38]. qPCR was undertaken using gene-
specific primers for E-cadherin with Power SYBR® Green
PCR Master Mix (TaKaRa, Japan). Normalization was
performed with β-actin. The following primers were used:
E-cadherin, forward 5'-GTCACTGACACCAACGATAAT
CCT-3' and reverse 5'-TTTCAGTGTGGTGATTACGA
CGTTA-3'; β-actin forward 5'-CACCAACTGGGACGAC
ATG-3' and reverse 5'-GCACAGCCTGGATAGCAAC-3'.
Transwell migration and Matrigel invasion assays
For transwell migration assays, 7.5 × 104 MHCC-97H
cells in 0.5 ml serum-free DMEM medium were added
to the top chamber, and the bottom chamber was filled
with 0.5 ml DMEM medium with 10 % FBS. After 24 h,
cells located on the upper surface were removed using a
cotton swab, and the cells on the lower surface were
fixed with 100 % methanol for 5 min, and then stained
with Wright-Giemsa at room temperature. For matri-
gel invasion assays, BD BioCoat Matrigel Invasion
Chambers (Catalog No. 354480) were used for the
invasion assay according to the instructions of the
manufacturer. To quantify the migratory and invasive
Table 1 Correlation of RARγ expression with patients’ clinicopathological variables in 56 cases of HCCC
Characteristics All cases (N = 56) RARγ expression (%)
Low (n = 21) High (n = 35) χ2 value p value
Gender 0.221 0.639
Male 47 17 30
Female 9 4 5
Age (years) 1.026 0.311
≤ 50 15 4 11
> 50 41 17 24
Tumor size (cm) 5.265 0.022
≤ 3 8 5 3
> 3 48 11 37
Cirrhosis 0.076 0.783
Negative 28 10 18
Positive 28 11 17
HBV infection 0.327 0.567
Negative 4 9
Positive 17 26
Distant metastasis 8.443 0.004
No 26 15 11
Yes 30 6 24
TNM stage 8.310 0.004
I/II 41 20 21
III/IV 15 1 14
Differentiation 0.448 0.799
Well 6 3 3
Moderate 25 9 16
Poor 25 9 16
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cells microscopically, cells were counted in five ran-
dom fields (magnification, 200×).
Metastasis of Xenografts
In this study, 1 × 106 MHCC-97H/shRNA/Control or
MHCC-97H/shRNA/RARγ cells were injected into the
lateral vein in the nude mouse tail (BALB/c, SPF grade,
4–5 weeks, male). After 7 weeks, mice of each group
were killed. Lung tissues were collected for metastatic
foci evaluation and standard histopathological study. All
animal experiments were approved by the Animal Care
and Use Committee of Soochow University.
Statistical analysis
Each assay was performed in three independent experi-
ments. Data were presented as mean ± s.d. Statistical sig-
nificance was analyzed using Student's t-test (unpaired,
two-tailed) or one-way ANOVA. The relationships be-
tween RARγ expression and clinicopathological factors
were analyzed using Pearson’s chi-square test, and the
correlations between the expression levels of RARγ and
E-cadherin were calculated using Spearman's rank Cor-
relation analysis. The Kaplan-Meier survival analysis was
used to illustrate the prognostic relevance of RARγ in
univariate analysis. p < 0.05 was considered statistically
significant.
Results
RARγ is elevated in HCC specimens and correlates with
distant metastasis and poor survival
To determine the role of RARγ in HCC invasion and
metastasis, western blotting was first performed to
examine the expression of RARγ in human HCC tissues.
Compared with the matched surrounding tissues of
HCC, an overexpression of RARγ was detected in the
primary HCC tumors (Fig. 1a). Furthermore, we exam-
ined gene expression data from Oncomine, and found
that RARγ mRNA levels are significantly upregulated in
HCC tissues compared with liver cancer precursor tis-
sues (Fig. 1b). In agreement with these results, by ana-
lyzing an additional 56 cases HCC samples, we found
that RARγ expression is overexpressed in tumor tissues
(Fig. 1c and d), and further upregulated in those with
lymph node metastasis (LNM) (Fig. 1e and f), suggesting
RARγ’s potential role in invasive progression of HCC.
We further analyzed the relationship between the
levels of RARγ expression and the clinicopathological
status of patients with HCC. As shown in Table 1,
patients with higher RARγ expression are significantly
associated with larger tumor size, distant metastasis and
high TNM stage of HCC. However, there is no signifi-
cant correlation between RARγ expression and other
clinicopathological features, such as patient gender, age,
cirrhosis, HBV infection and differentiation.
We next sought to determine whether RARγ expres-
sion in HCC is associated with patient survival time.
Kaplan-Meier analysis revealed that patients with high
RARγ expression have poorer overall survival. The
median survival time of HCC patients with high RARγ
expression was < 20 months, while the median survival
time was significantly longer (~70 months) in those with
low RARγ expression (Fig. 1g). These data suggest that
elevated RARγ expression may contribute to HCC pro-
gression and its expression may be a valuable predicting
factor for survival in HCC patients.
Knockdown of RARγ expression inhibits HCC cell
migration and invasion in vitro, and metastasis in vivo
The above findings indicate the involvement of elevated
RARγ expression in HCC aggressiveness. Based on these
findings, we investigated whether RARγ plays a critical
role in regulating HCC cell invasion and metastasis. We
first used a lentiviral-mediated shRNA technique to sta-
bly knock down RARγ expression in MHCC-97H cell
lines that express a high level of RARγ protein. The
knockdown efficiency was confirmed by western blotting
(Additional file 1: Figure S1). Migration assays show that
knockdown of RARγ largely impairs the ability of HCC
cell migration, as compared with control cells (Fig. 2a
and b). Similarly, invasion assays also reveal that knock-
down of RARγ potently inhibits HCC cell invasive prop-
erties (Fig. 2c and d). We further examined the effect of
RARγ on HCC metastasis by establishing mouse model
for studying HCC metastasis in vivo. MHCC-97H cells
having high metastatic potential were used for the study.
Our results show that depletion of RARγ greatly impairs
HCC metastasis to the lungs, indicated by the fact that
MHCC-97H/shRNA/Control cells form more and larger
pulmonary micrometastases than the MHCC-97H/
shRNA/RARγ cells (Fig. 2e). These findings are also
summarized in Fig. 2f. Evidently, these results indicate
that RARγ acts to promote the invasive property of
HCC cells in vitro and in vivo.
RARγ regulates E-cadherin expression
Given that RARγ contributes to HCC invasion and me-
tastasis, we investigated that the effect of RARγ on
EMT, a critical event in cancer cell invasion and metas-
tasis. Interestingly, as shown in Fig. 3a, knockdown of
RARγ in MHCC-97H cells significantly enhanced the
expression of E-cadherin, an epithelium marker in EMT.
This result was also confirmed by immunofluorescent
staining (Fig. 3b). Conversely, overexpression of RARγ in
Huh-7 cells that express a low level of RARγ protein
markedly decreased E-cadherin expression as revealed
by the western blot (Fig. 3c) and immunofluorescent
staining (Fig. 3d). However, we did not observe any sig-
nificant change in expression of other EMT markers
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such as Vimentin, N-cadherin and occludin (Additional
file 2: Figure S2). We next examined whether ATRA, an
agonist for RARs, has an effect on E-cadherin expres-
sion. Our results show that treatment of Huh-7 cells
with ATRA enhances RARγ-induced E-cadherin reduc-
tion (Fig. 3e). However, ATRA has no significant effect
on the MHCC-97H cells in which RARγ is knocked
down by siRNA (Fig. 3f ), suggesting that RARγ-
mediated E-cadherin reduction can be regulated by
its ligands.
RARγ-induced E-cadherin reduction is dependent on
NF-κB Activation
The next task was to address how RARγ regulates E-
cadherin expression. Huh-7 cells were treated with
MG132, an inhibitor of protease, and then E-cadherin






















































































































Fig. 1 Increased levels of RARγ in HCC correlates with distant metastasis and predicts poor clinical outcome. a RARγ expression in HCC samples
was evaluated by western blotting. Four randomly selected pairs of HCC tumors (T) and matched surrounding tissues (S) are presented. b Box
plot shows the mRNA levels of RARγ expression in 38 human HCC and 58 human liver cancer precursor tissues. Statistical significance was determined
by a two-tailed, unpaired Student's t-test. c Representative bright-field images showing RARγ staining (brown) in human HCC sections. Nuclei (blue)
were marked by hematoxylin staining. Scale bar: 100 μm. T, tumor. S, surrounding tissue. d Scatter plot analysis of RARγ levels in 56 HCC tissue samples
and their surrounding tissues. Statistical significance was determined by a two-tailed, paired Student's t-test. **p < 0.01. e Representative bright-field
images showing RARγ staining (brown) in human HCC tissues with distant metastasis (N = 30) and without distant metastasis (N = 26). Nuclei (blue)
were marked by hematoxylin staining. Scale bar: 100 μm. f Scatter plot analysis of RARγ levels in human HCC tissues with distant metastasis (N = 30)
and without distant metastasis (N = 26). Statistical significance was determined by a two-tailed, unpaired Student's t-test. **p < 0.01. g Kaplan-Meier
survival curve of HCC patients with low (n = 44) and high (n = 46) RARγ expression
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protein and mRNA levels were examined. However,
RARγ-induced E-cadherin reduction at protein and
mRNA levels was not affected by MG132 (Fig. 4a), indi-
cating the regulation of E-cadherin expression by RARγ
may occur at the transcriptional level. Real-time PCR
assays further confirmed that silencing RARγ in MHCC-
97H cells markedly induced E-cadherin mRNA expression
(Fig. 4b), while ectopic RARγ expression in MHCC-97H
cells largely impaired E-cadherin mRNA expression in a
dose-dependent manner (Fig. 4c).
Given the fact that RARγ, like other nuclear receptors,
can act as a transcription factor to regulate expression of
its target gene through binding to its DNA response ele-
ments [39, 40], it is possible that RARγ may bind to the
promoter of E-cadherin to regulate its expression. How-
ever, after sequence analysis of the region of E-cadherin
promoter between -2000 bp and -1 bp, we did not find a
potential RARγ binding site within the region (data not
shown), suggesting that RARγ-driven E-cadherin reduc-
tion might be mediated by other molecules or signaling
pathways. Interestingly, in the process of exploring which
molecular or signaling pathway was involved in RARγ-
induced E-cadherin reduction, we were surprised to find
that BMS-345541, an inhibitor of NF-κB signaling path-
way, completely blocked RARγ-induced E-cadherin reduc-
tion both at mRNA levels (Fig. 4d) and at protein levels
(Fig. 4e) in Huh-7 cells. This suggests that the activation
of NF-κB signaling is required for RARγ-induced E-
cadherin reduction. To further confirm this finding, we
treated MHCC-97H with tumor necrosis factor α (TNFα),
an agonist against the NF-κB signaling pathway, and
found that TNFα significantly enhanced RARγ-induced
E-cadherin reduction (Fig. 4f ) and greatly impaired up-
regulation of E-cadherin by silencing RARγ (Fig. 4g). To-
gether, these results demonstrate that NF-κB signaling is
indispensable for the regulation of E-cadherin by RARγ.
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Fig. 2 Silencing RARγ impaires HCC migration and invasion in vitro and metastasis in vivo. a–d Migration (a) and invasion (c) assays were performed
in wild-type MHCC-97H cells (shRNA/Control) and in the MHCC-97H cells with stable knock down of RARγ (shRNA/ RARγ), and the relative number of
migratory (b) and invasive (d) cells were calculated with Wright-Giemsa staining. e Knockdown of RARγ inhibits HCC metastasis. Representative lung
tissue sections from each group were shown by hematoxylin and eosin staining (magnification: × 40). Black arrows indicate lung tissues with matastatic
nodules. f The number of lung metastatic foci in each group (n = 6 per group) was counted under the microscope. Statistical significance was
determined by a two-tailed, unpaired Student's t-test. **p < 0.01
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RARγ expression is negatively correlated with E-cadherin
expression in HCC cell lines and clinical HCC samples
To further examine the RARγ-E-cadherin relationship,
we analyzed the expression of RARγ and E-cadherin in
HCC cell lines and clinical HCC samples. Interestingly,
we notice a significant correlation in the expression of
RARγ and E-cadherin both at the mRNA (Fig. 5a and b)
and protein (Fig. 5c and d) levels in six HCC cell lines.
The correlation of RARγ and E-cadherin was further
validated by examining the expression of these two mol-
ecules in 56 cases of HCC tissues using immunohisto-
chemical staining. Our results showed that low RARγ
expression was associated with high E-cadherin expres-
sion in Case 1 (Fig. 5e). Inversely, the high levels of
RARγ correlated with the low levels of E-cadherin in
Case 2 (Fig. 5e). Spearman's Rank Correlation analysis
confirmed that there is a significant negative correlation
between RARγ and E-cadherin expression (Fig. 5f ).
Thus, these observations further strengthened our find-
ing that RARγ promotes HCC invasion and metastasis
through regulation of E-cadherin reduction.
Discussion
Emerging evidence suggests that aberrant expression of
nuclear receptor RARγ contributes to cancer develop-
ment and progression [30, 31, 34]. In our previous stud-
ies, RARγ was identified as an oncogene that was
associated with hepatocellular tumorigenesis by activat-
ing PI3K/Akt and NF-κB signaling pathway [31]. An
overexpression of RARγ was found in HCC tissues, and
its expression was closely correlated with the prolifera-
tion and growth of HCC cells [31], indicating its critical
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Fig. 3 RARγ regulates E-cadherin expression. a, b silencing RARγ increases endogenous levels of E-cadherin proteins. MHCC-97H cells stably
expressed shRNA/Control or shRNA/RARγ, then (a) total cell lysates were subjected to immunoblotting to determine E-cadherin levels, or (b) the
cells were subjected to immunofluorescent staining of E-cadherin (red). Nuclei was stained with DAPI (blue). Representative images are shown.
c, d RARγ overexpression decrease endogenous E-cadherin protein levels. Huh-7 cells were transiently transfected with vector or Myc-tagged
RARγ, then endogeous protein levels of E-cadherin were detected by immunoblotting (c) or immunofluorescent staining (d). e, f The role of ATRA
in RARγ-induced E-cadherin downregulation. Immunoblotting of E-cadherin in RARγ-transfected Huh-7 cells (e) or in RARγ-silenced MHCC-97H
cells (f) treated with vehicle or 1 μM ATRA. #, no specific band
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role in HCC development. However, it remains unclear
whether aberrant expression of RARγ performs key roles
in HCC invasion and metastasis.
In this study, we determined the significance and
underlying mechanism for RARγ in HCC invasion and
metastasis. The RARγ expression was markedly higher
in HCC tissues with distant metastasis than in those
HCC tissues without distant metastasis, suggesting a key
role of RARγ in HCC progression. Analyzing the rela-
tionship between RARγ expression and pathological
characteristics in 56 HCC patients by tissue microarray
revealed a significant correlation of RARγ expression
with TNM stages and distant metastasis. Kaplan-Meier
analysis further showed that RARγ expression was
closely correlated with the overall survival of HCC pa-





Fig. 4 NF-κB is indispensable for RARγ-driven E-cadherin reduction. a RARγ-driven E-cadherin reduction does not depend on proteasome pathway.
Immunoblotting (left) or qPCR (right) analysis of the E-cadherin expression in RARγ-transfected Huh-7 cells treated with vehicle or 10 μM MG132.
b, c RARγ regulates E-cadherin at transcriptional level. qPCR analysis of the E-cadherin expression in RARγ siRNA-transduced MHCC-97H and QGY-7703
cells (b) or RARγ-transfected MHCC-97H cells (c). d, e BMS-345541 inhibits RARγ-driven E-cadherin reduction. qPCR (d) or immunoblotting (e) analysis
of the E-cadherin expression in RARγ-transfected Huh-7 cells treated with vehicle or 10 μM BMS-345541. f, g TNFα promotes RARγ-driven E-cadherin
reduction. Immunoblotting analysis of the levels of E-cadherin expression in RARγ-transfected Huh-7 cells (f) or RARγ siRNA-transduced MHCC-97H cells
(g) treated with vehicle or 20 nM TNFα. Statistical significance was determined by a two-tailed, unpaired Student's t-test. **p < 0.01. ns, no significance
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considered a biomarker candidate for clinical HCC prog-
nosis. The effect of RARγ on HCC cells invasion and
metastasis was directly demonstrated in our in vitro and
in vivo studies. Silencing RARγ significantly inhibits the
invasive ability of HCC cells, and led to severe suppres-
sion of lung metastasis of HCC in mice. These observa-
tions are in good agreement with previous reports that
high levels of RARγ expression in cholangiocarcinoma
(CCA) promote CCA cell invasion [30].
Our current study demonstrated that RARγ acts as a
metastasis-promoting protein in HCC through regulat-
ing NF-κB-dependent E-cadherin reduction. EMT plays
a critical role in cancer metastasis. Cancer cells undergo-
ing EMT acquire invasive properties [41]. Accumulating
studies have revealed that EMT is a crucial mechanism
in cancer progression and metastasis, and many proteins
involve in this process [11]. In this study, we found that
RARγ is indeed involved in EMT. Modulation of RARγ
expression by siRNA or overexpression resulted in a sig-
nificant change in E-cadherin expression. Loss or reduc-
tion of E-cadherin, an epithelium marker, is a hallmark
of EMT. Loss or reduction of E-cadherin expression is
often associated with the tumor grade and stage [42].
Several molecules and signaling have been identified to
regulate E-cadherin expression by transcriptional or
post-transcriptional mechanism [21, 25, 43]. We recently
reported that upregulation of Nur77, an orphan member
of the nuclear receptor superfamily, confers colorectal
cancer invasive features through regulating MMP-9-




Fig. 5 The expression levels of RARγ and E-cadherin in HCC cell lines and clinical HCC tissues. a The expression of RARγ and E-cadherin were
evaluated by RT-PCR in the indicated cell lines. b Dot plot correlates the mRNA levels of RARγ and E-cadherin in HCC cell lines. The dotted line shows
the negative correlation of RARγ and E-cadherin at the mRNA levels. c Immunoblotting analysis of RARγ and E-cadherin expression in the indicated cell
lines. d The dot plot correlates RARγ and E-cadherin protein levels in six HCC cell lines. The dotted line shows the negative corralation of RARγ and
E-cadherin at the protein levels. e Immunohistochemical staining of RARγ and E-cadherin in human CRC tissues. Representative bright-field images
showing RARγ and E-cadherin staining in human HCC sections. Scale bar: 100 μm. f Spearman’s correlation analysis between RARγ and E-cadherin in
56 cases of HCC tissues
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finding reported here is that we identified inflammatory
signaling NF-κB is involved in RARγ-driven EMT.
Inhibition of NF-κB activity by pharmaceutical markedly
impaired RARγ-induced E-cadherin reduction, while
enhancement of NF-κB activity by inflammatory cyto-
kine TNFα greatly promoted RARγ-induced E-cadherin
reduction. These results suggest a requirement for
inflammatory signaling NF-κB in RARγ-driven EMT. It
is worthwhile to point out that recent studies revealed
that NF-κB-mediated Snail stabilization might trigger
inflammation-induced cancer cell migration and inva-
sion [44]. This finding, together with ours, is in agreement
with the notion that inflammatory tumor microenviron-
ment facilitates both tumor development and metastatic
progression. Indeed, epidemiologic studies have provided
overwhelming evidence that chronic inflammation with
hepatitis B virus (HBV) or hapatitis C virus (HCV) infec-
tions contributes to HCC development [6, 7], and exten-
sive studies have revealed that genetically or chemically
induced HCC depends on inflammatory signaling [45, 46].
Although we previously reported that RARγ-driven in-
flammatory signaling NF-κB promotes hepatocellular
tumorigenesis [31], whether the mechanism also accounts
for HCC invasion and metastasis is unknown. We here
demonstrate that a key role of RARγ in induction of HCC
metastasis through regulation of NF-κB-mediated E-
cadherin downregulation.
Conclusions
In summary, we have identified RARγ as a key regulator
of HCC invasion and metastasis. RARγ upregulation in
HCC cells and HCC tissues contributes to their proinva-
sive and prometastatic abilities in vitro and in vivo by
regulating inflammatory signaling NF-κB-mediated E-
cadherin reduction. This may highlight a new therapeutic
opportunity for intervention of HCC metastasis by block-
ing RARγ-driven EMT.
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Additional file 1: Figure S1. The efficiency of RARγ depletion in
MHCC-97H. Immunoblotting of RARγ in MHCC-97H cells that stably
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MHCC-97H cells. Statistical significance was determined by a two-tailed,
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